Logo Image
|Articles|November 15, 2016

Physicians Want Strong FDA Biosimilar Naming

The Biologics Prescribers Collaborative has released findings from a physician’s survey about the FDA’s proposed biosimilar naming guidelines.

The Biologics Prescribers Collaborative has released findings from a physician’s survey about the FDA’s proposed biosimilar naming guidelines. According to the survey, 80 percent of physicians prefer a meaningful four-letter suffix that notes the biosimilar manufacturer’s name as opposed to a random four-letter suffix.

Read the full release here

Related to this article

View more
Better Site Training Starts With Five Simple Questions
Better Site Training Starts With Five Simple Questions
Site training effectiveness depends on readiness at first-patient-in, requiring learning-science design principles around performance focus, cognitive load reduction, progressive sequencing, and spaced retrieval practice rather than training completion metrics or content volume.
Read more